DWM
BBIO icon

Dogwood Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Dogwood Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.25K Sell
57
-41
-42% -$2.87K ﹤0.01% 538
2026
Q1 		$7.28K Buy
98
+48
+96% +$3.48K ﹤0.01% 397
2025
Q4 		$3.82K Buy
50
+41
+456% +$2.69K ﹤0.01% 471
2025
Q3 		$467 Buy
+9
New +$439 ﹤0.01% 653

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Dogwood Wealth Management's BBIO Position: Q2 2026 in Review

Dogwood Wealth Management reduced its BridgeBio Pharma (BBIO) stake by 42% in Q2 2026, selling an estimated $2.87K and leaving 57 shares worth $4.25K. The position accounts for ﹤0.01% of the portfolio, ranked #538.

Dogwood Wealth Management first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $7.28K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Dogwood Wealth Management held 57 shares of BridgeBio Pharma worth $4.25K as of Q2 2026.
  • Dogwood Wealth Management sold 41 BridgeBio Pharma shares in Q2 2026, an estimated $2.87K.
  • BridgeBio Pharma made up ﹤0.01% of Dogwood Wealth Management's portfolio in Q2 2026, its #538 holding.
  • Dogwood Wealth Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Dogwood Wealth Management's BridgeBio Pharma position peaked at $7.28K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Dogwood Wealth Management's 13F filing for Q2 2026, filed 6 Jul 2026.